Aditxt, Inc. (NASDAQ: ADTX) is a clinical-stage biotechnology company focused on the development of precision medicine solutions that leverage transcriptomic signatures to diagnose and treat acute and chronic conditions. The company’s core technology platform centers on the analysis of extracellular RNA (exRNA) biomarkers, enabling the creation of digital diagnostic assays and RNA-based therapeutic candidates. These proprietary tools aim to provide early detection of allograft rejection, acute inflammatory episodes, and other medical events where rapid decision-making is critical.
The company’s flagship offering is a digital diagnostic workflow designed for transplant medicine, utilizing high-throughput sequencing and custom bioinformatics to generate actionable insights for clinicians. Aditxt’s pipeline also includes RNA therapeutic programs targeting immune modulation, with development efforts directed toward reducing the reliance on broad-spectrum immunosuppression. By integrating its diagnostic and therapeutic platforms, Aditxt seeks to establish a seamless precision medicine ecosystem that can improve patient outcomes and optimize healthcare resource utilization.
Founded in 2016 and headquartered in Delray Beach, Florida, Aditxt maintains research and development operations across North America and Europe, with strategic collaborations in Asia and Australia. The company has forged partnerships with leading academic institutions, transplant centers, and contract research organizations to advance its pipeline through preclinical and clinical stages. These alliances underscore Aditxt’s commitment to building a robust global infrastructure for RNA-based innovation.
Aditxt is led by a management team with extensive experience in biotechnology product development, regulatory strategy, and commercial execution. The board and executive leadership draw on years of tenure at pharmaceutical and diagnostic companies, helping to steer the company’s program portfolio from early discovery through regulatory approval and market entry. This depth of expertise positions Aditxt to capitalize on the growing demand for precision diagnostics and RNA therapeutics.
AI Generated. May Contain Errors.
